MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market Jul 12, 2024 04:59PM
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders Jun 20, 2024 02:47AM
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders Jun 20, 2024 02:20AM
MorphoSys AG Reports First Quarter 2024 Financial Results Apr 29, 2024 04:01PM
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting Apr 24, 2024 10:40AM
View Older Stories

Apr 11, 2024 09:00AM MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Apr 11, 2024 08:40AM MorphoSys AG's (MOR) Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Apr 11, 2024 08:39AM MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Mar 22, 2024 02:58AM MorphoSys AG (MOR) Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis
Mar 22, 2024 02:50AM MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Mar 13, 2024 04:02PM MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Mar 7, 2024 04:15PM Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Feb 5, 2024 05:17PM MorphoSys AG (MOR) to be Acquired by Novartis for EUR 2.7B Equity Value
Feb 5, 2024 05:15PM MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Jan 30, 2024 05:42AM MorphoSys AG (MOR) Reports Prelim 2023 Monjuvi US Sales of $92M, Issues Guidance
Jan 30, 2024 03:15AM MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Jan 8, 2024 02:20AM MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 11, 2023 03:47AM MorphoSys (MOR) Reports Pelabresib Improved All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Dec 10, 2023 07:31PM MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Nov 20, 2023 04:30PM MorphoSys AG (MOR) Reports Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Nov 20, 2023 04:30PM MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Nov 15, 2023 04:01PM MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
Nov 9, 2023 04:20PM Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
Nov 2, 2023 09:45AM MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
Oct 25, 2023 05:32AM MorphoSys AG (MOR) Reports Prelim Q3 Monjuvi U.S. Sales of $23.4M, Updates Guidance for 2023
Oct 25, 2023 05:10AM MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Sep 12, 2023 04:54PM MorphoSys AG (MOR) Granted FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Sep 12, 2023 04:20PM MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Aug 9, 2023 04:01PM MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
May 3, 2023 04:01PM MorphoSys AG Reports First Quarter 2023 Financial Results
Apr 27, 2023 04:20PM Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
Apr 16, 2023 03:01PM MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
Mar 15, 2023 04:03PM MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 9, 2023 04:20PM Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
Mar 2, 2023 05:46AM MorphoSys AG (MOR) Stops Work and Operations on Pre-Clinical Research Programs
Mar 2, 2023 04:00AM Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
Mar 2, 2023 04:00AM MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
Jan 5, 2023 06:13AM MorphoSys AG (MOR) Reports Prelim 2022 Monjuvi US Sales of $89.4M, Guides 2023 Sales of $80M-$95M
Jan 5, 2023 06:00AM MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
Nov 28, 2022 04:30PM MorphoSys AG: Financial Calendar 2023
Nov 16, 2022 04:01PM MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
Nov 14, 2022 05:50AM MorphoSys' (MOR) Partner Roche Issues Update on Phase 3 GRADUATE Program for Gantenerumab
Nov 14, 2022 01:30AM MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
Nov 10, 2022 04:30PM Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
Nov 3, 2022 09:25AM MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Oct 27, 2022 04:22PM MorphoSys AG (MOR) Reports Prelim Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)
Oct 27, 2022 04:20PM MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
Oct 27, 2022 05:59AM MorphoSys AG (MOR) Announces GSK Issues Update on ContRAst Phase III Program for Otilimab
Oct 27, 2022 03:10AM GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
Oct 21, 2022 06:00AM MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Sep 28, 2022 04:03PM MorphoSys AG (MOR) Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi for Patients with R/R DLBCL
Sep 28, 2022 04:01PM MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
Aug 31, 2022 04:01PM MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters
Aug 3, 2022 04:01PM MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
Jul 28, 2022 04:20PM MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
View Older Stories